Previous | Next
861862863864865866867868869870871872873874875876877878879880881882883884885886887888889890891892893894895896897898899900901902903904905906907908909910911912913914915916917918919920921922923924925926927928929930 of 999
Yes, in the Phase I Trials Jordan Gutterman had, out of
eight patients, three that got very definite responses, especially
in breast cancer. Now, you've got something there.
I have an editorial which appeared in The New York Times on
Friday June 12th of this year. It's titled “Protracted War on
Cancer.” Since you've been so deeply involved in this whole
war on cancer, I think you can make a very cogent reply to this
one paragraph, which I shall read. This is a reference to a
Senate Labor and Human Resources Committee series of hearings,
which were held recently. “As the Senate keeps looking into
the cancer program, the most important questions it can ask
involve strategy and balance. How much effort should be devoted
to prevention as opposed to cure? How much to research as opposed
to treatment? How much focus on environment and diet as opposed
to viruses and drugs? Have the gains been worth the enormous
cost, or has the cancer war drained funds from equally important
Well, the cost of cancer is over $20 billion a year,
and that in the last ten years would have meant $200 billion.
In the whole ten years we have spent $7,500,000. I think we've
spent much too little on the subject, not too much.
The thing on how much should we spend on which aspect
of cancer is very puzzling, and that's why you need more
money to spend on all aspects of it.
© 2006 Columbia University
Libraries | Oral History
Research Office | Rights and
Permissions | Help